Purpose Obese women with breast cancer have worse prognosis than women with normal body mass index. Endocrine therapy resistance is in part mediated by insulin resistance in obese women with breast cancer. We investigated the tolerability and pharmacokinetics of exemestane in combination with metformin and rosiglitazone in nondiabetic overweight and obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Methods Patients had previously received chemotherapy and endocrine therapy for breast cancer. Exemestane was given as 25 mg orally per day. Metformin (M) and rosiglitazone (R) were given twice daily. Dose level 1 consisted of M 1,500 mg/day and R 6 mg/day. Dose level 2 consisted of M 2,000 mg/day and R 8 mg/day. Plasma concentrations of exemestane were measured on days 1, 8, and 15. Results Twenty patients were enrolled. Fourteen patients received exemestane, metformin, and rosiglitazone. Six patients received exemestane with metformin only (2,000 mg/day). Both regimens were well tolerated at the highest doses tested, and there were no notable changes in plasma exemestane levels. Six patients (30 %) had stable disease for 6 months or longer. Conclusions Oral daily administration of exemestane (25 mg) and metformin (2,000 mg) with and without rosiglitazone (8 mg) daily was well tolerated. Exemestane pharmacokinetics were not altered by metformin and rosiglitazone.
Introduction
Obesity is associated with an increased risk of developing postmenopausal breast cancer and is an independent prognostic factor in patients who have been diagnosed with breast cancer [23] . Up to 50 % of postmenopausal breast cancer deaths in the United States may be linked to obesity [33] . The effect of obesity on breast cancer risk is mediated by both insulin resistance and estrogen metabolism [35] . Estrogens, both exogenous and endogenous, are etiologic factors for breast cancer [40] . Estrogens stimulate cell proliferation through nuclear receptor-mediated gene regulation as well as other effects that increase mutation rates and aneuploidy. The biosynthesis of estrogens in adipose tissue in postmenopausal women is particularly important in the pathogenesis of estrogen receptor-positive breast carcinoma [30] . Hyperinsulinemia is associated with increased risk of breast cancer [24] . Both retrospective and prospective observational studies support a potential role of insulin-like growth factors (IGFs) in breast carcinogenesis [16, 19, 31] . Obese patients also have elevated serum concentrations of leptin (an adipokine), which contribute to their increased risk of developing breast cancer compared with lean patients with normal leptin levels [15] . A high serum level of adiponectin (another adipokine) is a risk factor for breast cancer in postmenopausal females [37, 38] . Thus, estrogens, adipokines such as leptin and adiponectin, insulin, and IGF-1 have been viewed as important factors in hormone receptor-positive (HR?) breast cancer carcinogenesis [11, 13] .
Aromatase inhibitors (AIs) are one of the standard treatments for postmenopausal women with HR? metastatic breast cancer [4, 8] . These include nonsteroidal, reversible AIs (e.g., anastrozole, letrozole) and the steroidal, irreversible AI (exemestane) [12] . Because most women treated with AI therapy in the adjuvant setting receive anastrozole or letrozole, patients with HR? breast cancer whose disease progresses after adjuvant treatment often receive exemestane, either front line or subsequently in the treatment of their metastatic disease [3, 10, 34] .
Metformin is approved for the treatment of type 2 diabetes mellitus. In one study of diabetic patients with early-stage breast cancer, those who received neoadjuvant chemotherapy with concomitant metformin had a higher rate of pathologic complete response than did those who received chemotherapy without metformin [20] . The mechanism of action of metformin in breast cancer cells is not fully understood but may involve activation of AMPK, inhibition of respiratory chain complex 1 and activation of G6PDH [26] . Furthermore, metformin can mimic the hepatic gene expression profile of long-term caloric restriction in mice and it can suppress breast cancer carcinogenesis in transgenic mice [2] . The effects on breast cancer, after breast cancer has formed in obese mice, are under investigation.
Rosiglitazone is a thiazolidinedione that activates PPARc receptors [9] to improve insulin resistance and it has been shown to cause a significant redistribution of fat away from viscera and liver with a concomitant increase in insulin sensitivity [27] . In obese women with polycystic ovary syndrome, rosiglitazone increases plasma concentration of adiponectin [28] . In breast cancer cells, thiazolidinediones have antineoplastic activity both in vitro and in vivo [7] .
While exemestane decreases estrogen level, metformin and rosiglitazone improve insulin resistance and lower insulin and IGF-1 concentration. In addition, both metformin and rosiglitazone treatment are associated with redistribution of body fat [14] . Furthermore, experimental data show that metformin and rosiglitazone have direct inhibitory effects on breast cancer cells [1, 2] . On the basis of preclinical evidence of the antitumor activity of metformin and rosiglitazone and the activity of exemestane in the treatment of HR? metastatic breast cancer, we investigated the tolerability of exemestane in combination with metformin and rosiglitazone in overweight and obese postmenopausal women with HR? metastatic breast cancer.
Patients and methods

Patients and study design
This was a phase I single-institution, open-label, doseescalation study (ClinicalTrials.gov identifier, NCT00933309) designed to assess the tolerability of metformin and rosiglitazone in combination with exemestane in postmenopausal overweight or obese women with HR? metastatic breast cancer. The postmenopausal status was defined by one of the following: (a) no spontaneous menses for more than 1 year in women [55 years old; (b) no spontaneous menses within the past 1 year in women B55 years old with postmenopausal gonadotrophin concentration (luteinizing hormone and follicle-stimulating hormone concentration [40 IU/L) or postmenopausal estradiol concentration (\10 pg/mL); or (c) bilateral oophorectomy. Overweight and obese are defined by the World Health Organization as a body mass index of 25.0-29.9 kg/m 2 and C30 kg/m 2 , respectively. All patients had a history of biopsy-proven estrogen receptor-positive (C10 %) and/or progesterone receptor-positive (C10 %) breast cancer and clinical evidence of metastatic disease. HER2-positive patients were not excluded. Prior endocrine therapy, biologic therapy, and chemotherapy were allowed, either adjuvantly or for metastatic breast cancer. Prior exemestane, metformin, or rosiglitazone were allowed if taken more than 7 days prior to enrollment. An Eastern Cooperative Oncology Group performance status score B2 was required for participation. Requirements for adequate organ function included an absolute neutrophil count C1,000/lL; platelets C75,000/lL; hemoglobin C8.5 g/dL; serum creatinine \1.4 mg/dL; bilirubin \1.8 mg/dL; alanine aminotransferase or aspartate aminotransferase B2.5 times the upper limit of the normal range if there were no demonstrable liver metastases or B5 times the upper limit of normal in the presence of liver metastases; alkaline phosphatase \3 times the upper limit of normal; calcium B11.0 mg/dL; and international normalized ratio \1.6. Patients had to be competent to give informed consent and to state that they understood the investigational nature of the proposed treatment.
Patients were ineligible if they had received extensive radiotherapy (C30 % of marrow-bearing bone, for example, whole pelvis or half spine) within the previous 4 weeks or if they had uncontrolled diabetes mellitus (hemoglobin A1C [9 or random plasma glucose [400 mg/dL), history of acromegaly, Cushing syndrome, Cushing disease, Addison disease (treated or untreated), unstable angina, or uncontrolled ischemic cardiac disease or symptomatic congestive heart failure (e.g., New York Heart Association class III or IV). Patients were not allowed to take hormone replacement therapy (estrogen with or without progesterone) or other investigational drugs within 3 weeks of registration on the protocol. Patients were excluded if they were known to have chronic liver diseases (e.g., chronic active hepatitis, cirrhosis) or human immunodeficiency virus infection. Patients could not have received chemotherapy within 3 weeks (6 weeks for nitrosourea or mitomycin-C). Acute toxic reactions to prior therapy had to have resolved to grade B1 with the exception of fatigue, alopecia, or anemia. The protocol was approved by the institutional review board at The University of Texas MD Anderson Cancer Center. Written informed consent was obtained from all patients.
The primary end point was to investigate a safe dosage and tolerance of metformin and rosiglitazone in combination with the FDA-approved dose of exemestane in overweight and obese postmenopausal women with HR? metastatic breast cancer. We evaluated the pharmacokinetics of exemestane and the clinical benefit of treatment as secondary end points. Safety assessments were made according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. Dose-limiting toxicity (DLT) was defined as: grade C3 nonhematologic toxicity; grade III nausea/vomiting, skin rash, and/or diarrhea (despite adequate supportive care); grade C3 skin toxicity not reverting to grade B2 within 14 days of the scheduled start date; febrile neutropenia [absolute neutrophil count (ANC) \1.0 9 10 9 /L and fever C38.5°C] and/or documented infection (ANC \1.0 9 10 9 /L); and grade IV thrombocytopenia or bleeding requiring a platelet transfusion.
All patients received 25 mg/day oral exemestane, which is the dose approved by the US Food and Drug Administration (FDA) for the treatment of metastatic breast cancer. The dose of exemestane was not modified throughout the study. The starting doses of the other agents were 1,500 mg/day metformin and 6 mg/day rosiglitazone (two patients). The dose level was escalated to dose level 2 (12 patients), as shown in Table 1 , if no DLT was observed and de-escalated if DLT was observed. Dose level 2 was considered the maximum tolerated dose if no DLT occurred. The first 14 patients enrolled received metformin plus rosiglitazone as the combination tablet Avandamet (GlaxoSmithKline, Research Triangle Park, NC). Six additional patients received single-agent 2,000 mg/day metformin (Glucophage XR, Bristol-Myers Squibb Company, New York, NY). A cycle was defined as 28 days. Treatment was continued until disease progression or intolerable toxic reactions occurred.
On each patient visit to the outpatient clinic, we obtained a medical history and conducted a physical examination. We evaluated vital signs and results of laboratory examinations, including complete blood cell count with differential, lipid profile, and concentration of blood urea nitrogen, creatinine, random glucose, calcium, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, lactate dehydrogenase, total bilirubin, and hemoglobin A1C (in patients with a history of diabetes mellitus). These tests were completed at baseline; at weeks 4, 8, and 12; and every 3 months (±7 days) thereafter. An electrocardiogram was obtained at baseline. Tumor assessment data using standard diagnostic imaging tests were required prior to registration to confirm metastatic disease. Re-staging imaging studies were completed every 2-3 months at the discretion of the treating physician.
Tolerability and efficacy evaluations
The study was conducted using a continual reassessment method (CRM) with a cohort size of two patients initially. The CRM is based entirely on a Bayesian decision framework. The Department of Biostatistics at MD Anderson has extensive experience with this methodology and has produced software implementing this method. The MD Anderson-developed CRM software assumes that the probability of toxicity at dose i (p i ) is modeled as p i = p i exp(a) , where p i is a constant and a is distributed a priori as a normal random variable with mean 0 and variance 2. The CRM software requires the investigator to specify the prior mean probability of toxicity at each of the four doses under consideration (s i , i = 1, 2, 3, 4). The CRM model assumes that toxicity increases with dose, and thus, the s i values must increase as i increases. The values p i in the probability model are selected so that 
After the first cohort, each successive cohort is given the dose whose posterior probability of toxicity, given the data collected thus far, is closest to the target toxicity (the software does not allow an untried dose to be skipped). Thus, as information accumulates, the model is continually updated posteriorly and decisions are made on the basis of the posterior distribution. As a result, no data are lost, and there is the assurance that the decision to increase or decrease the dose level is consistently reassessed as more information becomes available.
We began enrolling patients in our trial in September 2009. In September 2010, the FDA announced that it would restrict the use of rosiglitazone to patients with type 2 diabetes that could not be controlled by other medications. These new restrictions were implemented in response to data suggesting an elevated risk of cardiovascular events, such as heart attack and stroke, in diabetic patients treated with rosiglitazone [25] . Because of concerns regarding the unlikely future use of rosiglitazone in nondiabetic populations and the increasing interest in metformin's potential as a treatment for breast cancer, we amended our protocol. The last six patients enrolled received exemestane in combination with metformin (2,000 mg/day), without rosiglitazone.
Patients were assessed every 12 weeks for tumor response using standard clinical criteria. The clinical benefit rate was determined by the number of patients who achieved an objective response according to the Response Evaluation Criteria in Solid Tumors [18] plus those who had stable disease for at least 24 weeks. Complete response was defined as the disappearance of all known lesions for at least 4 weeks. Partial response was defined as C30 % decrease in the sum of the longest diameters of all measurable lesions.
Pharmacokinetic sampling, assay, and analysis Thirteen patients participated in the pharmacokinetic part of this study. Of these, five were overweight and eight were obese. These patients' mean height was 164 ± 6.01 cm, their mean weight was 85.9 ± 11.1 kg, and their mean body mass index was 31.9 ± 4.54 kg/m 2 ( Table 2) . Two of the patients in the pharmacokinetic study were treated on dose level 1, and 11 were treated at dose level 2. On day 1, blood samples (5 mL) were drawn predose and at 1, 3, 6, 12, and 23 h postdose. Blood samples were also drawn on days 8 and 15 at the same time points as day 1. Plasma samples were prepared from each blood sample and stored at -20°C until shipment to PRA International (Lenexa, KS) for pharmacokinetic analysis.
Exemestane concentrations in plasma were determined by solid phase extraction followed by ultra performance liquid chromatography coupled with tandem mass spectrometry (MS/MS, API 4400, Applied Biosystems Inc., Foster City, CA). The lower limit of quantitation was 0.1 ng/mL.
Pharmacokinetic parameters of exemestane were determined by noncompartmental analysis of plasma concentration versus time data using WinNonlin version 5.2 (Pharsight, Mountain View, CA). The area under the curve (AUC 0-24 ) was calculated using the linear trapezoidal rule 
Results
Patient characteristics
We enrolled 20 eligible patients between September 2009 and February 2011. The median body mass index was 33 (Table 3 ). All primary tumors were estrogen receptorpositive, and 14 were progesterone receptor-positive. Nineteen of the patients had clinical evidence of visceral and/or bone metastasis; one patient had soft tissue metastasis only. All patients had received prior chemotherapy or endocrine therapy for breast cancer. Nineteen patients had received prior chemotherapy for breast cancer. Six patients had received a nonsteroidal inhibitor in the adjuvant setting, and four received prior exemestane for metastatic disease.
Tolerability
Throughout the treatment period, we observed drugrelated adverse events (definite or probable) in most patients. These included mild (grade 1-2) nausea and diarrhea, similar to what would be expected for singleagent exemestane. We found no difference in toxicities between dose level 1 and dose level 2. No DLT was noted, and no dose reductions occurred. On a few occasions, at the attending physician's request the rosiglitazone and metformin treatment was suspended for a few days in one of the patients because of grade 2 diarrhea. None of the patients developed hypoglycemia (Table 4) . We observed grade 3 adverse events, which were not drug related, in five patients. A patient who developed grade 3 nausea and vomiting was found to have progressive disease with worsening pleural effusions as well as renal insufficiency. One patient with a history of inflammatory bowel syndrome experienced grade 3 nausea. One patient with liver and bone metastases was enrolled with grade 2 anemia (9.8 g/dL), and she developed grade 3 anemia while receiving treatment. Another patient experienced grade 3 diarrhea and fatigue secondary to lymphocytic colitis. One patient had intermittent grade 3 fatigue, which was attributed to worsening depression related to her diagnosis and prognosis.
Pharmacokinetics
Plasma concentration versus time values were captured on days 1, 8, and 15 and can be found in Fig. 1 . Plasma pharmacokinetic parameters are found in Table 5 . On day 1, t max , the time after administration at which exemestane reached its maximum concentration (C max ), was a mean 2.54 ± 1.81 h (range 1.00-6.00 h). After reaching C max , exemestane concentration declined in a biexponential manner, with a terminal oral half-life of 4.87 ± 1.13 h (range 3.47-7.64 h). Exposure to exemestane (both C max and AUC) was highly variable (Fig. 2) . The mean C max was 12.1 ± 11.6 ng/mL (range 2.2-39.3 ng/mL), while AUC 0-24 was 48.6 ± 29.5 h 9 ng/mL (range 11.0-127.0 h 9 ng/mL) and AUC 0-inf was 50.9 ± 30.0 h 9 ng/mL (range 12.6-131.0 h 9 ng/mL). Apparent CL/F was 663 ± 440 L/h (range 191-1,979 L/h), while the apparent terminal phase Vz/F was 4,405 ± 2,299 L (range 1,426-9,922 L). On days 8 and 15, t max occurred somewhat more rapidly, with the median t max decreasing to 1.92 ± 1.04 h (range 1.0-3.0) and 1.36 ± 0.81 h (range 1.0-3.0 h), respectively. Exposure to exemestane changed very little during 15 days of treatment. The mean C max was 11.30 ± 8.26 ng/mL (range 3.05-25.50 ng/mL) and 15.4 ± 17.0 ng/mL (range 5.09-64.5 ng/mL) for days 8 and 15, respectively. AUC 0-24 was 48.1 ± 36.7 h 9 ng/mL (range 11.7-142 h 9 ng/mL) and 52.1 ± 46.7 h 9 ng/mL (range 20.63-190 h 9 ng/mL) for days 8 and 15, respectively. As was the case for day 1, only a small fraction (about 6 % on average) of AUC 0-24 was extrapolated to AUC 0-inf . AUC 0-inf was 52.6 ± 39.0 h 9 ng/mL (range 13.2-147 h 9 ng/mL) and 55.2 ± 48.1 h 9 ng/mL (range 22.4-195 h 9 ng/mL) on days 8 and 15, respectively. As on day 1, C max and AUC 0-24 varied considerably on days 8 and 15 (Fig. 2) .
The mean half-life (T 1/2 ) of exemestane was 5.69 ± 2.40 h (range 1.69-10.4 h) on day 8 and 6.65 ± 2.34 h (range 3.00-11.50 h) on day 15, slightly longer compared with that observed on day 1. This increase appeared to be partly due to a somewhat larger Vz/F. On day 8, the mean Vz/F was 5,364 ± 3,001 L (range 1,238-10,375 L), increasing slightly to 5,812 ± 2,924 L 
Efficacy
None of the patients achieved a complete or partial response. Six patients (30 %) had stable metastatic disease for 6 months or longer (range 6-18 months). Four patients received metformin and rosiglitazone and achieved SD for 6, 6, 18, 18 months, respectively. Two patients received metformin alone and achieved SD for 10 and 11 months, respectively. One patient who had received prior anastrozole and exemestane for metastatic breast cancer achieved stable disease for 11 months with exemestane and metformin treatment. None of the other three patients who had received prior exemestane derived clinical benefit from the combination.
Discussion
This study showed that oral administration of exemestane is safe in combination with metformin and rosiglitazone in overweight and obese nondiabetic postmenopausal women with HR? metastatic breast cancer. The treatment was well tolerated, and no DLT was observed. Most patients experienced mild (grade 1-2) drug-related adverse events, mainly nausea and diarrhea, similar to what would be expected for single-agent exemestane. The combination was associated with clinical benefit in 30 % of patients who had had disease progression subsequent to previous conventional chemotherapy and endocrine therapy.
Upon its administration to postmenopausal overweight women with breast cancer, exemestane was rapidly absorbed and then eliminated in a biexponential manner with a mean half-life of 5-7 h. Exemestane had a rather high apparent terminal volume of distribution, which averaged about 4,400-5,800 L, consistent with wide distribution throughout body water and tissues. Although metabolites were not followed in this study, exemestane is known to be extensively metabolized by multiple cytochrome p450 (CYP) enzymes, including CYP3A4 [17, 39] , CYP1A2, CYP2B6, and CYP4A11 [22] . The oxidative metabolites 17-hydroexemestane and 6-hydroxyexemestane are the major metabolites of exemestane [5, 6] . Exemestane and its metabolites are ultimately excreted in the urine and feces [29] . Several studies were reviewed in which exemestane was administered to patients at a dose of 25 mg/day for various time periods with at least some pharmacokinetic data [5, 6, 17, 21, 29, 39] . As seen in Table 6 , the pharmacokinetic parameters of exemestane determined in this study proved comparable with the values obtained in prior studies, suggesting they were not affected by the addition of metformin and rosiglitazone in this population.
In the present study of exemestane administered concomitantly with obesity medications rosiglitazone and metformin, no treatment group received only exemestane; therefore, it was not possible to determine whether any drug interactions occurred with these two agents. However, it is known that rosiglitazone is mainly metabolized by CYP2C8 and, to a lesser extent, CYP2C9 [32] . Furthermore, metformin is rapidly eliminated through active secretion by the kidneys, and it is neither metabolized nor protein bound in plasma [36] . Thus, given that exemestane is mainly cleared by CYP3A4 metabolism, an important interaction with these two agents would not be expected. Several of the studies cited above measured exemestane pharmacokinetics in the presence of concomitant medications, including raloxifene [39] , celecoxib [6] , and tamoxifen [17] -also with no apparent drug interactions. This may be due to the fact that multiple CYPs play a role in exemestane metabolism.
A phase III randomized trial (MA.32) is in progress in North America to determine the efficaðcy and tolerability of adjuvant metformin in patients with early-stage breast cancer. However, significant questions regarding antineoplastic clinical benefits of metformin and/or thiazolidinediones still remain for obese/overweight breast cancer patients in the metastatic setting. The tolerability and pharmacokinetic data of exemestane supports further testing of aromatase inhibitors and metformin combinations in 
Accumulation ratio
Cmax AUCinf mean Cmax mean AUCinf C max AUC inf 1 The accumulation ratio is defined as the ratio of Cmax or AUC0-24 on day 15 to that on day 1 Fig. 3 Accumulation ratio of maximum concentration (C max ) and area under the curve (AUC 0-24 ) after administration of 25 mg/day exemestane to postmenopausal breast cancer patients. The accumulation ratio is defined as the ratio of C max or AUC 0-24 on day 15 to that on day 1 the metastatic setting for overweight postmenopausal women with HR? metastatic breast cancer.
